Insight from Beating AI News: At the company's IPO roadshow, Anthropic CEO Dario Amodei made a bold prediction: cancers, Alzheimer's disease, heart disease, and mental illnesses could become history within less than a decade. He believes that if AI risks are properly managed, humanity may enter a 'miracle era' capable of solving millennia-old challenges.
As early as 2024, Amodei proposed in his article 'Machines of Loving Grace' the concept of a 'compressed 21st century': leveraging AI with capabilities surpassing top scientists to condense medical breakthroughs that would normally take 50 to 100 years into just 5 to 10 years. He even envisioned AI reducing cancer incidence and mortality by over 95%, preventing Alzheimer’s disease, and extending average human lifespan from around 75 years to 150 years.
Amodei has firsthand experience with disease and medical progress. He once suffered from early-stage testicular cancer and successfully underwent treatment; his father passed away due to hepatitis C. Several years after his father’s death, new antiviral drugs emerged, achieving a cure rate of about 95%. In September this year, he revisited this experience, emphasizing how much earlier medical breakthroughs could mean for patients.
Anthropic has already begun actively participating in drug development. In October, the company disclosed collaborations with six biopharmaceutical institutions, including Bristol-Myers Squibb, and acquired Mithril Medicine, a drug research firm with only one full-time employee.
The founder of Mithril used Claude to manage experiments, analyze data, and coordinate 11 external laboratories, advancing a potential therapy for a rare muscle-wasting disease into animal testing in under 18 months. Some treated mice showed grip strength and muscle power approximately twice that of untreated controls, with improved survival rates. Anthropic expects that if subsequent trials proceed successfully, the drug could enter human clinical trials as early as late 2028.
While AI can accelerate drug design and data analysis, it cannot directly shorten the time required for therapeutic effects or long-term side effects to manifest in humans. Especially for chronic conditions like Alzheimer’s disease, researchers may need to track patients for years to confirm whether a new drug is truly effective.
Amodei previously acknowledged that clinical trials and regulatory approvals remain major bottlenecks in accelerating medicine. In an article published in June this year, he noted that new drugs typically require about 7 to 8 years to gain approval in the U.S. and Europe. He advocates using better AI simulations, toxicity predictions, and biomarkers to shorten development timelines while preserving essential safety validation.
At the conclusion of the IPO roadshow, Amodei emphasized that only companies capable of controlling AI risks and earning societal trust are qualified to sustainably develop and apply this technology. He linked the vision of curing major diseases with Anthropic’s long-standing focus on AI safety.